医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Haoxi Health Technology Limited Facilitates International Humanitarian Aid Efforts Amid Global Challenges

2024年06月10日 AM09:00
このエントリーをはてなブックマークに追加


 

BEIJING

Haoxi Health Technology Limited (the “Company” or “HAO”), an online marketing solution provider headquartered in Beijing, China, today announced that against the backdrop of increasing global challenges, the Company is mobilizing its resources to actively fulfill its corporate social responsibility and is closely monitoring international humanitarian needs and collaborating with relevant organizations and groups to provide essential support for international medical aid.

Amidst evolving global dynamics, numerous regions face pressing humanitarian needs. The Company, renowned for its expertise in digital marketing and commitment to social responsibility, is leveraging its capabilities to assist those in need.

HAO has established a dedicated service team, collaborating closely with international medical aid organizations to assess frontline medical supply requirements. Simultaneously, the Company is sourcing various urgently needed humanitarian relief supplies including medical equipment, pharmaceuticals, and protective gear, while meticulously planning donation strategies and delivery logistics.

Mr. Zhen Fan, Chairman and Chief Executive Officer of the Company, commented, “We firmly believe that corporate success is rooted in societal support and trust. Therefore, amid global challenges, the Company has a unique opportunity to make meaningful contributions to society. Through our international humanitarian aid initiative, the Company aims to play a significant role in alleviating humanitarian crises worldwide.

“Furthermore, the Company invites other companies and individuals to join this collaborative effort, because a collective action is needed to address global humanitarian challenges effectively.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20240609519886/en/

CONTACT

For more information, please contact:

Investor Relations

WFS Investor Relations Inc.

Janice Wang, Managing Partner

Email: services@wealthfsllc.com

Phone: +86 13811768599

+1 628 283 9214

同じカテゴリーの記事 

  • Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
  • Huonslab Announces Positive Results from In Vivo comparative PK study of Trastuzumab/HyDIFFUZETM compared with marketed rHuPH20 co-formulation with Trastuzumab
  • Rapid Medical™、TIGERTRIEVER™13を用いたDISTALS臨床試験の中間安全性解析で、中血管閉塞の安全性の懸念がないことを報告
  • Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
  • JCR Pharmaceuticals’ Data Presentations at SSIEM Annual Symposium 2024 Highlight Investigational Treatments for Lysosomal Storage Disorders